IMMUNIC, INC. (IMUX)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 21,369 | |||
| General and administrative | 5,714 | |||
| Total operating expenses | 27,083 | |||
| Loss from operations | -27,083 | |||
| Change in fair value of the tranche rights | - | |||
| Other income (expense), net | 22 | |||
| Interest income | 241 | |||
| Total other income (expense) | 263 | |||
| Net loss | -26,820 | |||
| Net loss per share, basic (in usd per share) | -0.2 | |||
| Net loss per share, diluted (in usd per share) | -0.2 | |||
| Weighted-average common shares outstanding, basic (in shares) | 132,175,202 | |||
| Weighted-average common shares outstanding, diluted (in shares) | 132,175,202 | |||